pf-03654746
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00531752)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorANTAGONIST
HRH3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCNC(=O)[C@H]1C[C@@](F)(c2ccc(CN3CCCC3)c(F)c2)C1- Mol. weight
- 322.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2151197 ↗
Also known as
- n-ethyl-3-fluoro-3-(3-fluoro-4-(pyrrolidinylmethyl)phenyl)cyclobutanecarboxamide
- pf03654746
- pf 03654746
- pf-03654746
- pf-03654746
- pf-03654746
- pf-03654746
- pf-03654746
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01475383 | Phase 2 | Apr 1, 2012 | Pfizer |
| NCT01028911 | Phase 1 | Dec 1, 2009 | Pfizer |
| NCT01006122 | Phase 2 | Nov 1, 2009 | Pfizer |
| NCT01346163 | Phase 1 | Apr 1, 2009 | Pfizer, University of Pennsylvania |
| NCT00730990 | Phase 1 | May 31, 2008 | Pfizer, Yale University |
| NCT00531752 | Phase 2 | Dec 1, 2007 | Pfizer |
| NCT00562120 | Phase 2 | Dec 1, 2007 | Pfizer |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 7 | 6 | 2 | 2007 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1